Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.
Postsurgical Pembrolizumab/Chemotherapy Misses DFS Goal in Endometrial Cancer
September 15th 2024While adjuvant pembrolizumab and chemotherapy with or without radiation did not boost DFS in the overall high-risk endometrial cancer population, but showed a trend toward improved DFS in one patient subgroup.